HSD3B1 and metastatic neoplasm: In patients who developed metastatic disease at any time, the cumulative incidence of PCSM at 5 years after development of metastases was higher in the HSD3B1 CC genotype group (36.0%; 95% CI, 16.7%-50.8%) compared with the AC genotype group (17.9%; 95% CI, 10.5%-24.7%) and AA genotype group (18.5%; 95% CI, 12.0%-24.6%) (P = .01) (Figure 3).